ImmunoGen Announces Resignation of Chief Financial Officer
“We thank Dave for his many contributions to ImmunoGen over the last
five years,” said
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in Phase 3 study for folate receptor alpha (FRα)-positive platinum resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
This press release includes forward-looking statements, including
those on Mr. Johnston’s remaining employed through year-end and then
serving as a consultant, Mr. Foster continuing in his role, ImmunoGen's
ability to transition to a fully integrated biotechnology company, and
the regulatory and commercial potential of our product candidates.
Important factors could cause ImmunoGen's actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date of
this release. It should be noted that there are risks and uncertainties
related to the retention of employees and consultants, the development
of novel anticancer products, including risks related to preclinical and
clinical studies, their timings and results, the potential that earlier
clinical studies may not be predictive of future results, and building a
commercial organization. A review of these risks can be found under
“Risk Factors” in ImmunoGen's Annual Report on Form 10-K for the year
INVESTOR RELATIONS CONTACT
THRUST Strategic Communications